SG10201608148TA - Methods Of Treating Epilepsy Or Status Epilepticus - Google Patents
Methods Of Treating Epilepsy Or Status EpilepticusInfo
- Publication number
- SG10201608148TA SG10201608148TA SG10201608148TA SG10201608148TA SG10201608148TA SG 10201608148T A SG10201608148T A SG 10201608148TA SG 10201608148T A SG10201608148T A SG 10201608148TA SG 10201608148T A SG10201608148T A SG 10201608148TA SG 10201608148T A SG10201608148T A SG 10201608148TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- status epilepticus
- treating epilepsy
- epilepsy
- treating
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title 1
- 208000005809 status epilepticus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261691545P | 2012-08-21 | 2012-08-21 | |
| US201361789491P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201608148TA true SG10201608148TA (en) | 2016-11-29 |
Family
ID=50148516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501911RA SG11201501911RA (en) | 2012-08-21 | 2013-08-21 | Methods of treating epilepsy or status epilepticus |
| SG10201608148TA SG10201608148TA (en) | 2012-08-21 | 2013-08-21 | Methods Of Treating Epilepsy Or Status Epilepticus |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501911RA SG11201501911RA (en) | 2012-08-21 | 2013-08-21 | Methods of treating epilepsy or status epilepticus |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US20140057885A1 (en) |
| EP (2) | EP3957309A1 (en) |
| JP (3) | JP6355633B2 (en) |
| KR (2) | KR102305359B1 (en) |
| CN (2) | CN104736159A (en) |
| AU (4) | AU2013305767B2 (en) |
| BR (2) | BR122021022560B1 (en) |
| CA (1) | CA2882708A1 (en) |
| CY (1) | CY1125070T1 (en) |
| DK (1) | DK2887944T3 (en) |
| ES (1) | ES2902684T3 (en) |
| HK (1) | HK1209025A1 (en) |
| HR (1) | HRP20220005T1 (en) |
| HU (1) | HUE056838T2 (en) |
| IL (5) | IL304912A (en) |
| LT (1) | LT2887944T (en) |
| MX (1) | MX2015002252A (en) |
| NZ (1) | NZ705410A (en) |
| PH (2) | PH12015500482A1 (en) |
| PL (1) | PL2887944T3 (en) |
| PT (1) | PT2887944T (en) |
| RS (1) | RS62761B1 (en) |
| RU (2) | RU2667010C2 (en) |
| SG (2) | SG11201501911RA (en) |
| SI (1) | SI2887944T1 (en) |
| WO (1) | WO2014031792A2 (en) |
| ZA (1) | ZA201501188B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2812250T3 (en) | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Ganaxolone formulations and procedures for their preparation and use |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CA2862076C (en) | 2012-01-23 | 2020-04-21 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| DK2925327T3 (en) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolone for the treatment, reduction or relief of symptoms of postpartum depression |
| US10172870B2 (en) | 2014-09-02 | 2019-01-08 | The Texas A&M University System | Method of treating organophosphate intoxication by administration of neurosteroids |
| JOP20200195A1 (en) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| US10668041B2 (en) | 2014-12-08 | 2020-06-02 | Societe Des Produits Nestle Sa | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
| PT3229790T (en) | 2014-12-08 | 2020-01-22 | Nestle Sa | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
| CN115487313A (en) * | 2015-02-06 | 2022-12-20 | 马瑞纳斯制药公司 | Intravenous ganaxolone formulations and uses thereof |
| US10441580B2 (en) * | 2015-02-17 | 2019-10-15 | Vanda Pharmaceuticals, Inc. | Iloperidone for the treatment of schizophrenia |
| MA45276A (en) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE |
| WO2017066626A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| JOP20170059B1 (en) * | 2016-03-08 | 2021-08-17 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| RU2019103590A (en) | 2016-07-11 | 2021-02-11 | Сейдж Терапьютикс, Инк. | C17-, C20- AND C21-SUBSTITUTED NEUROACTIVE STEROIDS AND METHODS OF THEIR APPLICATION |
| US20180042903A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| US20200276209A1 (en) * | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| WO2019075362A1 (en) | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| WO2019094724A1 (en) * | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| US11446262B2 (en) | 2018-11-29 | 2022-09-20 | Debora Zucco Sassi Yonezawa Siviglia | Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination |
| WO2020113099A1 (en) * | 2018-11-29 | 2020-06-04 | Gary Aaron Howard | Method for treating or preventing seizures associated with an epileptic disorder |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| JP2022543837A (en) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ， インコーポレイテッド | Ganaxolone for use in treating status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| JP2023503928A (en) | 2019-12-06 | 2023-02-01 | マリナス ファーマシューティカルズ， インコーポレイテッド | Ganaxolone for use in the treatment of tuberous sclerosis |
| CN113368084A (en) * | 2020-03-10 | 2021-09-10 | 上海喀露蓝科技有限公司 | Pharmaceutical composition containing cannabidiol, propofol prodrug and allopregnanolone prodrug compound and application of pharmaceutical composition in medicines |
| WO2021195297A1 (en) | 2020-03-25 | 2021-09-30 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| CA3184353A1 (en) * | 2020-05-29 | 2021-12-02 | Cerecin Inc. | Methods for the treatment of infantile spasms using medium chain triglycerides |
| CN113925832B (en) * | 2020-07-13 | 2023-06-16 | 苏州特瑞药业股份有限公司 | Allopregnanolone liposome and preparation method thereof |
| WO2022109440A1 (en) * | 2020-11-23 | 2022-05-27 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of super refractory status epilepticus |
| WO2023060020A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of established status epilepticus |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5847009A (en) | 1986-01-14 | 1998-12-08 | Alliance Pharmaceutical Corp. | Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| ES2155543T3 (en) * | 1994-11-23 | 2001-05-16 | Cocensys Inc | ANDROSTAN AND PREGNAN SERIES FOR ALLOSTERIC MODULATION OF THE GABA RECEIVER. |
| US6780853B1 (en) * | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| ATE272394T1 (en) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | DELAYED RELEASE PREPARATION |
| US7630757B2 (en) * | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6316613B1 (en) | 1997-07-25 | 2001-11-13 | Beckman Coulter, Inc. | Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis |
| US6442887B2 (en) | 2000-02-25 | 2002-09-03 | Robert L. Sanquist | Live bait keeper |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| GR1003861B (en) * | 2000-12-29 | 2002-04-11 | Novel gabaa modulating neurosteroids | |
| WO2003076476A2 (en) | 2002-01-14 | 2003-09-18 | Ansell Healthcare Products, Inc. | Magnetically detectable latex articles |
| US7550155B2 (en) | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| US7816074B2 (en) * | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
| ITMI20041763A1 (en) | 2004-09-16 | 2004-12-16 | Altergon Sa | NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE |
| US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| AU2006226774B2 (en) * | 2005-03-24 | 2010-12-02 | Emory University | Methods for the treatment of central nervous system injury via a tapered administration of progesterone |
| AU2006235318A1 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| WO2009003199A1 (en) * | 2007-06-28 | 2008-12-31 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090074677A1 (en) * | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| ES2589139T3 (en) | 2007-06-15 | 2016-11-10 | Research Triangle Institute | Androstane and pregnan steroids with potent allosteric modulation properties of the GABA / ionophore chloride receptor complex |
| DE102008015366A1 (en) | 2008-03-20 | 2009-09-24 | Merck Patent Gmbh | Lyophilised nanoemulsion |
| DK2313111T3 (en) * | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-like receptor agonist formulations and their use |
| PT2356109T (en) * | 2008-10-10 | 2017-03-10 | Vm Discovery Inc | Compositions and methods for treating alcohol use disorders, pain and other diseases |
| CN102300566A (en) * | 2008-11-30 | 2011-12-28 | O·扎查尔 | Dermal Application Of Vasoconstrictors |
| US20110306579A1 (en) * | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| JP5930311B2 (en) * | 2010-01-21 | 2016-06-08 | ドローブリッジ ファーマシューティカルズ プロプライエタリー リミテッド | Anesthetic preparation |
| BR112013010342A8 (en) * | 2010-11-03 | 2018-04-03 | Sanofi Aventis Deutschland | module containing medicine and needle cannula |
| WO2012075286A2 (en) * | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| FR2973031B1 (en) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | DERIVATIVES OF ALLOPREGNANOLONE AND EPIALLOPREGNANOLONE AND USES THEREOF FOR TREATING A NEUROPATHOLOGICAL CONDITION |
| CA2862076C (en) * | 2012-01-23 | 2020-04-21 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| US20140050789A1 (en) * | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
-
2013
- 2013-08-21 HU HUE13830765A patent/HUE056838T2/en unknown
- 2013-08-21 EP EP21200457.6A patent/EP3957309A1/en active Pending
- 2013-08-21 SG SG11201501911RA patent/SG11201501911RA/en unknown
- 2013-08-21 SG SG10201608148TA patent/SG10201608148TA/en unknown
- 2013-08-21 JP JP2015528638A patent/JP6355633B2/en active Active
- 2013-08-21 SI SI201331956T patent/SI2887944T1/en unknown
- 2013-08-21 KR KR1020207015890A patent/KR102305359B1/en active IP Right Grant
- 2013-08-21 ES ES13830765T patent/ES2902684T3/en active Active
- 2013-08-21 EP EP13830765.7A patent/EP2887944B1/en active Active
- 2013-08-21 PL PL13830765T patent/PL2887944T3/en unknown
- 2013-08-21 KR KR1020157007115A patent/KR102121633B1/en active IP Right Grant
- 2013-08-21 IL IL304912A patent/IL304912A/en unknown
- 2013-08-21 IL IL275725A patent/IL275725B/en unknown
- 2013-08-21 MX MX2015002252A patent/MX2015002252A/en unknown
- 2013-08-21 AU AU2013305767A patent/AU2013305767B2/en active Active
- 2013-08-21 HR HRP20220005TT patent/HRP20220005T1/en unknown
- 2013-08-21 US US13/972,851 patent/US20140057885A1/en not_active Abandoned
- 2013-08-21 BR BR122021022560-5A patent/BR122021022560B1/en active IP Right Grant
- 2013-08-21 CN CN201380053788.6A patent/CN104736159A/en active Pending
- 2013-08-21 IL IL294306A patent/IL294306B2/en unknown
- 2013-08-21 CN CN202010325813.3A patent/CN111529537A/en active Pending
- 2013-08-21 PT PT138307657T patent/PT2887944T/en unknown
- 2013-08-21 BR BR112015003747A patent/BR112015003747A2/en not_active Application Discontinuation
- 2013-08-21 LT LTEPPCT/US2013/056062T patent/LT2887944T/en unknown
- 2013-08-21 DK DK13830765.7T patent/DK2887944T3/en active
- 2013-08-21 CA CA2882708A patent/CA2882708A1/en active Pending
- 2013-08-21 WO PCT/US2013/056062 patent/WO2014031792A2/en active Application Filing
- 2013-08-21 RS RS20211597A patent/RS62761B1/en unknown
- 2013-08-21 RU RU2015109956A patent/RU2667010C2/en active
- 2013-08-21 RU RU2018132041A patent/RU2018132041A/en unknown
- 2013-08-21 NZ NZ705410A patent/NZ705410A/en unknown
-
2015
- 2015-02-20 ZA ZA2015/01188A patent/ZA201501188B/en unknown
- 2015-02-22 IL IL237352A patent/IL237352B/en active IP Right Grant
- 2015-03-05 PH PH12015500482A patent/PH12015500482A1/en unknown
- 2015-09-24 HK HK15109426.8A patent/HK1209025A1/en unknown
-
2018
- 2018-03-29 US US15/940,505 patent/US20190038639A1/en not_active Abandoned
- 2018-06-12 JP JP2018111924A patent/JP6829224B2/en active Active
- 2018-08-22 AU AU2018220028A patent/AU2018220028B2/en active Active
-
2019
- 2019-01-22 IL IL264414A patent/IL264414B/en active IP Right Grant
- 2019-05-22 US US16/419,761 patent/US20190269699A1/en not_active Abandoned
-
2020
- 2020-01-07 PH PH12020500065A patent/PH12020500065A1/en unknown
- 2020-06-30 AU AU2020204359A patent/AU2020204359A1/en not_active Abandoned
-
2021
- 2021-01-21 JP JP2021007791A patent/JP2021059608A/en active Pending
-
2022
- 2022-01-05 CY CY20221100012T patent/CY1125070T1/en unknown
- 2022-02-03 US US17/592,244 patent/US20220152050A1/en active Pending
- 2022-04-05 AU AU2022202277A patent/AU2022202277A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294306A (en) | Methods of treating epilepsy or status epilepticus | |
| HK1213771A1 (en) | Methods of treating cancer | |
| HK1219414A1 (en) | Methods of treating arthritis | |
| HK1216393A1 (en) | Methods of treating gastrointestinal spasms | |
| HK1210962A1 (en) | Methods for treatment of atherosclerosis | |
| EP2892536A4 (en) | Method of treating leukemia | |
| IL260115A (en) | Methods of treating fibrosis | |
| HRP20181000T1 (en) | Methods of treating hair related conditions | |
| HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
| PT2811993T (en) | Methods of treating fibrosis | |
| GB201221118D0 (en) | Methods of treatment | |
| GB201216740D0 (en) | Methods of treatment | |
| GB201216748D0 (en) | Methods of treatment | |
| GB201206326D0 (en) | Methods of treatment | |
| GB201206330D0 (en) | Methods of treatment | |
| GB201206325D0 (en) | Methods of treatment | |
| GB201206324D0 (en) | Methods of treatment | |
| GB201221032D0 (en) | Method of treatment | |
| GB201207894D0 (en) | Method of treatment |